Zenflow raises $31m in Series A

Urology medical device maker Zenflow said today it closed a $31.4 million Series A round of financing to support the development of minimally invasive devices designed to treat obstructive urinary symptoms related to benign prostatic hyperplasia. The round was led by Invus Opportunities, F-Prime Capital Partners and Medical Technology Venture Partners and was joined by other new and existing investors, the San Francisco-based company said. Zenflow said it has also received grant funding from the National Institutes of Health and the National Science Foundation. The company’s first product is the Spring System device, which is designed to deliver a low-profile superelastic implant into the prostatic urethra. The system is intended to allow for a simple, physician-led procedure to relieve BPH symptoms with a fast recovery time and minimal side effects. Financing from the current round will be used to support further clinical studies exploring the safety and effectiveness of the Spring System and preparations for a commercial launch. Zenflow said it plans to begin enrolling patients in a trial of the device in the UK, Australia, New Zealand and Mexico this year as it pursues FDA Investigational Device Exemption approval to launch a pivotal trial in the US. “The Zenflow Spring System is a promising new treatment option for men suffering from BPH symptoms. The device can be deployed in a simple procedure in the urologist’s office under direct visualization throug...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Urology zenflow Source Type: news